37 results about "Immunological memory" patented technology

Streptococcus pneumoniae is a major cause of pneumoniae, meningitis, and major cause of morbidity and mortality throughout the world by bacterial otitis media, pneumoniae, meningitis, and bacteraemia. It is an important agent of disease in man especially among infants, the elderly and immunocompromised persons. The present invention provides a solution to this problem by providing a substantially pure or isolated disease related antigen selected from the group consisting of the isolated, recombinant or synthetic S. pneumoniae human immunogenic antigens of SP_0562, SP_0965, SP_0082 (in particular the fragments SP4 and SP 17 of said SP_0082), and a Periplasmic Binding Protein (PBP) (in particular SP_1683 or SP_1386), or a fragments thereof or substantially identical antigen for use in a treatment to induce a immunological memory in a human against S. pneumoniae cells for use in a vaccination treatment of S. pneumoniae disorder in human or against S. pneumoniae in a human. In a particular embodiment, the present invention provides an isolated, recombinant or synthetic S. pneumoniae Periplasmic Binding Protein (PBP) (in particular SP_1683 or SP_1386) as a disease related antigen for use in a treatment to induce a immunological memory in a human against S. pneumoniae cells for use in a vaccination treatment of S. pneumoniae disorder in human or for use in the treatment of an S. pnewnoniae infection in a human. It further provides antibodies that specifically bind to the S. pneumoniae disease related antigens identified herein for use in the treatment of a an S. pneumoniae infection in a human, such as for example in a treatment to induce immunological memory in a human against S. pneumoniae, i.e. in a vaccination treatment of S. pneumoniae. It is also an aspect of the present invention to provide the use of any one of the S. pneumoniae disease related antigens as identified herein, or of the antibodies specific for said antigens in methods to diagnose for a S. pneumoniae disorder in a human.

The invention discloses a logistic distribution partitioning balance optimizing method, which builds a logistic distribution partitioning multipurpose optimal model and designs immune algorithm solving. A model minimizes zone line number as well as the total distance and the total working time of all lines to balance the line number, the total distance, the total working time and the total demanded quantity of different zones. The model adopts VRP, TSP and a shortest path algorithm to ensure the optimization of a distribution path while balancing zones. An arithmetic operator and a mechanism aroused by designed immunity comprise clonal selection, high-frequency variation, immune clearance and immunological memory, and two stages are searched to solve by the synergy of the construction and the zone of the initial partitioning scheme. The method of the invention is suitable for the partitioning balance optimization of large-scale logistic distribution, and can lower logistic distribution cost, improve logistic distribution efficiency and improve the degree of satisfaction of customers to staff.

The invention discloses a robot path planning method. A direction operator is introduced on the basis of an artificial fish swarm algorithm to improve the accuracy and the success rate of fish swarm behaviors such as clustering, tailgating and even foraging, and an immunological memory operation is added to improve the global searching capability of the algorithm and reduce the probability of local extreme values. Simulation experiments in two typical grid map environments show that compared with a fast genetic algorithm and an artificial fish swarm algorithm, the immunological-directional artificial fish swarm algorithm has the advantages of better result stability, shorter calculation time and feasible solution closer to the optimal path.

The present invention discloses a method of inhibiting CD8+ T cell deletion by the liver via the use of Toll-like receptor-4 inhibitors. Also disclosed are compositions of Toll-like receptor-4 inhibitors and either immunogenic agents or activated CD8+ T cells, which can be used to enhance secondary immune responses in normal and immunocompromised subjects. The administration of Toll-like receptor-4 inhibitors, alone or in combination with one or both of immunogenic agents or activated CD8+ T cells, to subjects to enhance secondary immune responses is also disclosed.

The structural design, preparative methods and chemical composition of two structural formulations of bivalent vaccines against morphine-heroin addiction (morphine-6-hemisuccinyl-EDC-TFCS-tetanus toxoid and 3-O-carboxymethylmorphine-EDC-TFCS-tetanus toxoid), are disclosed. These vaccines are suitable for human use in which they are capable of triggering the synthesis of polyclonal antibodies against morphine opiate and its structural analogue, heroin, through the repeated in vivo administration of these formulations, in active vaccination protocols, in pre-clinical studies in rodents. The active vaccination paradigm through which these immunogens trigger a humoral immune response consolidated with a long-term immunological memory, characterized by the presence of high titers of specific antibodies against these two drugs of abuse, is also disclosed. Furthermore, the present invention reveals the efficacy of these conjugate formulations for triggering a sustained immunoprotection against morphine and heroin addiction using an intravenous self-administration paradigm of these two opiate substances in the rodent. Finally, a discussion is also made on the potential future use of these immunoconjugates in active vaccination protocols for treating both morphine and heroin addiction in the humans.

Methods of monitoring and measuring dynamic adaptive immune cell responses are provided. High-throughput sequencing of T cell receptor and immunoglobulin loci is used to characterize the breadth of an effector cell response to a stimulus, such as a vaccine or infection. Unique responding effector cell clones and abundance thereof can be determined. Additionally, methods for determining the contribution of responding effector cells to the immunological memory compartment are provided.

The invention discloses a nucleic acid and recombinant protein co-immune vaccine based on a classical swine fever virus gene as well as a preparation method and application of the co-immune vaccine. The preparation method comprises the steps that firstly, optimized recombinant plasmids and recombinant classical swine fever vaccine antigen protein are obtained by combining gene engineering and cellengineering; then the nucleic acid sequence and the recombinant protein are compounded into different liquid phase layers of a biphasic adjuvant, so that the obtained co-immune vaccine is good in immunogenicity and short in immune blank period, can rapidly induce an organism to generate high-level, high-affinity and durable antibody response and immune memory, effectively protects a target animalfrom being attacked by classical swine fever virulent viruses, and the method can be applied to preparation of products for preventing/treating classical swine fever.

The invention discloses application of C-type CpG M362 in HBV preventive and therapeutic vaccines as an adjuvant and a preparation method of the HBV preventive and therapeutic vaccines. Compared withthe traditional HBV preventive vaccines, the HBV preventive vaccines taking the CpG M362 as the adjuvant have the maximum advantages that an organism can be induced to generate high-level body fluid response, and the cell response of the organism can be enhanced. Meanwhile, by applying the HBV therapeutic vaccines taking the CpG M362 as the adjuvant into clinical HBV treatment, a hepatic immunosuppression microenvironment caused by chronic HBV infection can be improved, immune tolerance caused by the HBV infection can be reversed, the cell response and body fluid response of the organism can be enhanced, and thus, HBV is completely cleared out. More importantly, after immunization of the vaccines taking the CpG M362 as the adjuvant, the organism can be induced to form long-term immunological memory, the organism can be protected from HBV reinfection, and a novel effective policy is provided for the clinical prevention of the HBV and the treatment of chronic HBV.

The present invention provides an antibody or fragment thereof that expresses an activated receptor (OX40) on the surface of activated CD4+T, CD8+T cells, and the use of the antibody or fragment thereof for the prevention or treatment of diseases. The antibody disclosed by the invention is high in affinity to OX40 and obvious in effect of activating an OX40 signal channel; the antibody has a relatively broad-spectrum immunopotentiation effect, and can enhance T cell response immune memory; and good tumor inhibiting and killing effects are achieved in animal model in-vivo experiments, and good clinical application prospects are achieved.

The invention provides an antigen and adjuvant co-delivery nano vaccine based on protamine as a carrier. The nano vaccine comprises a carrier, an antigen and an adjuvant, wherein the carrier is protamine sulfate; The invention also provides a preparation method and application of the vaccine. The nano vaccine prepared by the invention can effectively improve uptake efficiency of antigen presentingcells on antigens and adjuvants, efficiently stimulate maturation of the antigen presenting cells, assist the antigens in realizing cross presentation, significantly improve in-vivo transfer efficiency of the antigens and the adjuvants, stimulate a body to produce high-efficiency humoral immunity and cellular immunity, and at the same time produce an immune memory effect. In-vivo treatment is carried out on mouse subcutaneous melanoma, and it is proved that the nano vaccine has a good anti-tumor immunotherapy effect. The nano vaccine is simple in structure, convenient to prepare and excellentin immunotherapy performance, and has good application potential.

Formulations and preparations having immune memory enhanced properties are disclosed that provide for enhancing immune response against a tumor growth, cancer, infectious agent, bacteria, virus or other infectious or non-infectious agent. The vaccine formulation includes an immune memory invoking component, such as an antigen of an infectious agent, virus (e.g., Rabies), bacteria, prion, neo-antigen or other moiety antigen, and a targeted antigen (e.g., a harvested tumor tissue (B-cell, T-cell, epitopes)). The vaccine formulation/preparations may comprise a target infectious agent protein/peptide component (such as a SARS-Cov-2 spike protein epitope) mixed with, or fused to (or otherwise conjugated) an immune-memory associated viral antigen (such as Rabies, polio, or other peptide/protein antigen or peptide or fragment thereof).

The invention discloses a Golgi apparatus and genetic engineering exosome hybrid membrane coated retinoic acid in-situ spray hydrogel vaccine as well as a preparation method and an application thereof, and belongs to the technical field of medicines. In particular to a retinoic acid in-situ spray hydrogel vaccine which inhibits exosome PD-L1 secretion, reproduces lymph node immune cells to trigger immune memory so as to activate systemic immune response and is coated with a Golgi apparatus and genetic engineering exosome hybrid membrane and an application of the retinoic acid in-situ spray hydrogel vaccine in inhibition and/or treatment of postoperative recurrence of melanoma.

The invention provides application of an SUMF2 gene in preparation of a medicine for preventing allergic asthma attack and reducing airway hyperresponsiveness and belongs to the technical field of biomedicine. According to the application, a bioinformatics technology and an animal experiment verify that abnormality of a metabolic pathway of an SUMF1/2-glycosaminoglycan enables epithelial cells to generate an immune-memory-similar phenomenon, and a TH2 reaction can be promoted when the SUMF1/2-glycosaminoglycan is in contact with allergens again. According to the application, 20 days before asthma is induced, an adeno-associated virus vector is utilized to over-express the SUMF2 gene derived from epithelial cells of an airway of a mouse, and compared with a control group, the airway inflammatory response of lungs of asthmatic mice can be obviously improved. Therefore, the overexpressed SUMF2 can be used as a genetherapy target for preventing allergic asthma and reducing the airway hyperresponsiveness. Therefore, the use of the adeno-associated virus for overexpression of the SUMF2 in the field of prevention of the allergic asthma has a wide application value and a broad market prospect.

The invention discloses an intelligent immune self-healing method and system for a ship regional distribution power system. The method comprises the following steps of detecting a fault of the ship regional distribution power system, generating an intelligent immune self-healing scheme of the ship regional distribution power system, and enabling the ship regional distribution power system to intelligently execute fault recovery. The ship regional distribution electric power immune system has memory ability, the generated fault characteristics are recorded through the immune memory ability of B cells, and the fault can be quickly identified when occurring again. And a ship regional distribution power system fault self-healing global optimal scheme can be rapidly obtained. The ship regional distribution electric power immune system has a diversity maintaining capability, and in order to deal with various faults, the diversity of antibody groups is maintained by inhibiting antibodies with too high concentration, and the global convergence of an algorithm is ensured.

The invention discloses an adjuvant-free single-dose HBsAg nanogel vaccine and a preparation method thereof. The preparation method of the adjuvant-free single-dose HBsAg nanogel vaccine comprises the following step: under a constant-temperature stirring condition, mixing CS, HBsAg and a gamma-PGA solution step by step to prepare the positive-charge or negative-charge adjuvant-free single-dose HBsAg nanogel vaccine. The positive-charge HBsAg nanogel vaccine can obtain effective antibody expression only by single-dose injection, so that the immunity of cells is enhanced, the compliance of a vaccinator can be better improved, and general implementation of HBV prevention is guaranteed. The adjuvant-free single-dose HBsAg nanogel vaccine can induce formation of immunological memory to perform long-acting immunity protection on the vaccinator. The negative-charge HBsAg nanogel vaccine has no obvious generation of antibodies through single-dose injection, but when applied in combination with the positive-charge HBsAg nanogel vaccine, can obtain stronger cell immunity, and can better perform long-acting immunity protection on HBV.